The American College of Physicians updated its set of guidelines on the pharmacologic treatment of primary osteoporosis based on current evidence and research.
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
